Canaccord downgraded Doximity (DOCS) to Hold from Buy with a price target of $60, up from $40. The firm recognizes that Doximity is “currently executing flawlessly,” beating estimates and guidance. However, with the 30% gain in shares post-earnings, it appears the expectation to a return to the years of really robust growth, 20% or much higher, is increasingly being priced into the stock, the analyst tells investors in a research note. Canaccord believes it is appropriate to step back on recommending putting new money to work “with such high expectations.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DOCS:
- Doximity price target raised to $75 from $52 at Barclays
- Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz
- Doximity rises 35.0%
- Doximity price target raised to $60 from $35 at Leerink
- Doximity rises 36.5%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
